drug · small molecule
ibrutinib
Marketedupdated 6mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $3.5B
community read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 40 investigational indications.
targets
Tyrosine-protein kinase BTK
all catalysts(0)
nothing on the calendar yet
Trials studying ibrutinib
- phase3A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
- phase3A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
- phase3A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
- phase2Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
- phase1A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants
- —Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
- phase2Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
- phase3Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 28, 2026
36 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (448)
- Jun 14, 2039formulationUS 12201690
- Sep 3, 2036patentUS 10010507*PED
- Sep 3, 2036patentUS 10010507*PED
- Sep 3, 2036patentUS 10010507*PED
- Sep 3, 2036patentUS 10010507*PED
- Sep 3, 2036patentUS 10213386*PED
- Sep 3, 2036patentUS 10213386*PED
- Sep 3, 2036patentUS 10213386*PED
- Sep 3, 2036patentUS 10213386*PED
- Sep 3, 2036patentUS 10828259*PED
- Sep 3, 2036patentUS 10828259*PED
- Sep 3, 2036patentUS 10828259*PED
- Sep 3, 2036patentUS 10828259*PED
- Sep 3, 2036patentUS 9655857*PED
- Sep 3, 2036patentUS 9655857*PED
- Sep 3, 2036patentUS 9655857*PED
- Sep 3, 2036patentUS 9655857*PED
- Apr 6, 2036formulationUS 12364698
- Mar 3, 2036formulationUS 10010507
- Mar 3, 2036formulationUS 10010507
- Mar 3, 2036formulationUS 10010507
- Mar 3, 2036formulationUS 10010507
- Mar 3, 2036formulationUS 10213386
- Mar 3, 2036formulationUS 10213386
- Mar 3, 2036formulationUS 10213386
- Mar 3, 2036formulationUS 10213386
- Mar 3, 2036formulationUS 10828259
- Mar 3, 2036formulationUS 10828259
- Mar 3, 2036formulationUS 10828259
- Mar 3, 2036formulationUS 10828259
- Mar 3, 2036formulationUS 12551448
- Mar 3, 2036formulationUS 12551448
- Mar 3, 2036formulationUS 12551448
- Mar 3, 2036formulationUS 9655857
- Mar 3, 2036formulationUS 9655857
- Mar 3, 2036formulationUS 9655857
- Mar 3, 2036formulationUS 9655857
- Apr 24, 2035patentUS 10463668*PED
- Apr 24, 2035patentUS 10463668*PED
- Apr 24, 2035patentUS 10463668*PED
- Apr 24, 2035patentUS 10463668*PED
- Apr 24, 2035patentUS 10463668*PED
- Apr 24, 2035patentUS 10463668*PED
- Apr 24, 2035patentUS 10695350*PED
- Apr 24, 2035patentUS 10695350*PED
- Apr 24, 2035patentUS 10695350*PED
- Apr 24, 2035patentUS 10695350*PED
- Apr 24, 2035patentUS 10695350*PED
- Apr 24, 2035patentUS 10695350*PED
- Apr 24, 2035patentUS 9795604*PED
- Apr 24, 2035patentUS 9795604*PED
- Apr 24, 2035patentUS 9795604*PED
- Apr 24, 2035patentUS 9795604*PED
- Apr 24, 2035patentUS 9795604*PED
- Apr 24, 2035patentUS 9795604*PED
- Apr 24, 2035patentUS 9795604*PED
- Oct 24, 2034method-of-use (U-2654)US 10463668
- Oct 24, 2034method-of-use (U-2654)US 10463668
- Oct 24, 2034method-of-use (U-2654)US 10463668
- Oct 24, 2034method-of-use (U-2654)US 10463668
- Oct 24, 2034method-of-use (U-2654)US 10463668
- Oct 24, 2034method-of-use (U-2654)US 10463668
- Oct 24, 2034method-of-use (U-2970)US 10463668
- Oct 24, 2034method-of-use (U-2846)US 10695350
- Oct 24, 2034method-of-use (U-2970)US 10695350
- Oct 24, 2034method-of-use (U-2846)US 10695350
- Oct 24, 2034method-of-use (U-2846)US 10695350
- Oct 24, 2034method-of-use (U-2846)US 10695350
- Oct 24, 2034method-of-use (U-2846)US 10695350
- Oct 24, 2034method-of-use (U-2846)US 10695350
- Oct 24, 2034method-of-use (U-2969)US 9795604
- Oct 24, 2034method-of-use (U-2969)US 9795604
- Oct 24, 2034method-of-use (U-2970)US 9795604
- Oct 24, 2034method-of-use (U-2970)US 9795604
- Oct 24, 2034method-of-use (U-2970)US 9795604
- Oct 24, 2034method-of-use (U-2969)US 9795604
- Oct 24, 2034method-of-use (U-2969)US 9795604
- Apr 30, 2034patentUS 9296753*PED
- Apr 30, 2034patentUS 9296753*PED
- Apr 30, 2034patentUS 9296753*PED
- Apr 30, 2034patentUS 9296753*PED
- Apr 30, 2034patentUS 9296753*PED
- Apr 30, 2034patentUS 9296753*PED
- Apr 30, 2034patentUS 9296753*PED
- Feb 18, 2034patentUS 9540382*PED
- Feb 18, 2034patentUS 9540382*PED
- Dec 3, 2033patentUS 10106548*PED
- Dec 3, 2033patentUS 10106548*PED
- Dec 3, 2033patentUS 10106548*PED
- Dec 3, 2033patentUS 10106548*PED
- Dec 3, 2033patentUS 10106548*PED
- Dec 3, 2033patentUS 10106548*PED
- Dec 3, 2033patentUS 10106548*PED
- Dec 3, 2033patentUS 10125140*PED
- Dec 3, 2033patentUS 10125140*PED
- Dec 3, 2033patentUS 10125140*PED
- Dec 3, 2033patentUS 10125140*PED
- Dec 3, 2033patentUS 10125140*PED
- Dec 3, 2033patentUS 10125140*PED
- Dec 3, 2033patentUS 10125140*PED
- Dec 3, 2033patentUS 10294231*PED
- Dec 3, 2033patentUS 10294231*PED
- Dec 3, 2033patentUS 10294232*PED
- Dec 3, 2033patentUS 10294232*PED
- Dec 3, 2033patentUS 10752634*PED
- Dec 3, 2033patentUS 10752634*PED
- Dec 3, 2033patentUS 10961251*PED
- Dec 3, 2033patentUS 10961251*PED
- Dec 3, 2033patentUS 10961251*PED
- Dec 3, 2033patentUS 10961251*PED
- Dec 3, 2033patentUS 10961251*PED
- Dec 3, 2033patentUS 10961251*PED
- Dec 3, 2033patentUS 10961251*PED
- Dec 3, 2033patentUS 9713617*PED
- Dec 3, 2033patentUS 9713617*PED
- Dec 3, 2033patentUS 9725455*PED
- Dec 3, 2033patentUS 9725455*PED
- Dec 3, 2033patentUS 9725455*PED
- Dec 3, 2033patentUS 9725455*PED
- Dec 3, 2033patentUS 9725455*PED
- Dec 3, 2033patentUS 9725455*PED
- Dec 3, 2033patentUS 9725455*PED
- Oct 30, 2033compositionUS 9296753
- Oct 30, 2033compositionUS 9296753
- Oct 30, 2033compositionUS 9296753
- Oct 30, 2033compositionUS 9296753
- Oct 30, 2033compositionUS 9296753
- Oct 30, 2033compositionUS 9296753
- Oct 30, 2033compositionUS 9296753
- Aug 18, 2033method-of-use (U-1650)US 9540382
- Aug 18, 2033method-of-use (U-1684)US 9540382
- Jun 3, 2033compositionUS 10106548
- Jun 3, 2033compositionUS 10106548
- Jun 3, 2033compositionUS 10106548
- Jun 3, 2033compositionUS 10106548
- Jun 3, 2033compositionUS 10106548
- Jun 3, 2033compositionUS 10106548
- Jun 3, 2033compositionUS 10106548
- Jun 3, 2033compositionUS 10125140
- Jun 3, 2033compositionUS 10125140
- Jun 3, 2033compositionUS 10125140
- Jun 3, 2033compositionUS 10125140
- Jun 3, 2033compositionUS 10125140
- Jun 3, 2033compositionUS 10125140
- Jun 3, 2033compositionUS 10125140
- Jun 3, 2033formulationUS 10294231
- Jun 3, 2033formulationUS 10294231
- Jun 3, 2033formulationUS 10294232
- Jun 3, 2033formulationUS 10294232
- Jun 3, 2033formulationUS 10752634
- Jun 3, 2033formulationUS 10752634
- Jun 3, 2033formulationUS 10961251
- Jun 3, 2033formulationUS 10961251
- Jun 3, 2033formulationUS 10961251
- Jun 3, 2033formulationUS 10961251
- Jun 3, 2033formulationUS 10961251
- Jun 3, 2033formulationUS 10961251
- Jun 3, 2033formulationUS 10961251
- Jun 3, 2033formulationUS 9713617
- Jun 3, 2033formulationUS 9713617
- Jun 3, 2033compositionUS 9725455
- Jun 3, 2033compositionUS 9725455
- Jun 3, 2033compositionUS 9725455
- Jun 3, 2033compositionUS 9725455
- Jun 3, 2033compositionUS 9725455
- Jun 3, 2033compositionUS 9725455
- Jun 3, 2033compositionUS 9725455
- Dec 3, 2031patentUS 10004746*PED
- Dec 3, 2031patentUS 10004746*PED
- Dec 3, 2031patentUS 10004746*PED
- Dec 3, 2031patentUS 10004746*PED
- Dec 3, 2031patentUS 10004746*PED
- Dec 3, 2031patentUS 10004746*PED
- Dec 3, 2031patentUS 10016435*PED
- Dec 3, 2031patentUS 10016435*PED
- Dec 3, 2031patentUS 10016435*PED
- Dec 3, 2031patentUS 10016435*PED
- Dec 3, 2031patentUS 10016435*PED
- Dec 3, 2031patentUS 10016435*PED
- Dec 3, 2031patentUS 10478439*PED
- Dec 3, 2031patentUS 10478439*PED
- Dec 3, 2031patentUS 10478439*PED
- Dec 3, 2031patentUS 10478439*PED
- Dec 3, 2031patentUS 10478439*PED
- Dec 3, 2031patentUS 10478439*PED
- Dec 3, 2031patentUS 10478439*PED
- Dec 3, 2031patentUS 10653696*PED
- Dec 3, 2031patentUS 10751342*PED
- Dec 3, 2031patentUS 10751342*PED
- Dec 3, 2031patentUS 10751342*PED
- Dec 3, 2031patentUS 10751342*PED
- Dec 3, 2031patentUS 10751342*PED
- Dec 3, 2031patentUS 10751342*PED
- Dec 3, 2031patentUS 8754090*PED
- Dec 3, 2031patentUS 8999999*PED
- Dec 3, 2031patentUS 8999999*PED
- Dec 3, 2031patentUS 8999999*PED
- Dec 3, 2031patentUS 8999999*PED
- Dec 3, 2031patentUS 8999999*PED
- Dec 3, 2031patentUS 8999999*PED
- Dec 3, 2031patentUS 9125889*PED
- Dec 3, 2031patentUS 9125889*PED
- Dec 3, 2031patentUS 9125889*PED
- Dec 3, 2031patentUS 9125889*PED
- Dec 3, 2031patentUS 9125889*PED
- Dec 3, 2031patentUS 9125889*PED
- Dec 3, 2031patentUS 9801881*PED
- Dec 3, 2031patentUS 9801881*PED
- Dec 3, 2031patentUS 9801881*PED
- Dec 3, 2031patentUS 9801881*PED
- Dec 3, 2031patentUS 9801881*PED
- Dec 3, 2031patentUS 9801881*PED
- Dec 3, 2031patentUS 9801883*PED
- Dec 3, 2031patentUS 9801883*PED
- Dec 3, 2031patentUS 9801883*PED
- Dec 3, 2031patentUS 9801883*PED
- Dec 3, 2031patentUS 9801883*PED
- Dec 3, 2031patentUS 9801883*PED
- Dec 3, 2031patentUS 9814721*PED
- Jun 3, 2031method-of-use (U-2241)US 100047464.5y
- Jun 3, 2031method-of-use (U-3847)US 100047464.5y
- Jun 3, 2031method-of-use (U-2242)US 100047464.5y
- Jun 3, 2031method-of-use (U-2242)US 100047464.5y
- Jun 3, 2031method-of-use (U-1684)US 100047464.5y
- Jun 3, 2031method-of-use (U-1946)US 100047464.5y
- Jun 3, 2031method-of-use (U-2241)US 100047464.5y
- Jun 3, 2031method-of-use (U-1650)US 100164354.5y
- Jun 3, 2031method-of-use (U-1650)US 100164354.5y
- Jun 3, 2031method-of-use (U-1650)US 100164354.5y
- Jun 3, 2031method-of-use (U-1650)US 100164354.5y
- Jun 3, 2031method-of-use (U-3845)US 100164354.5y
- Jun 3, 2031method-of-use (U-1650)US 100164354.5y
- Jun 3, 2031method-of-use (U-1650)US 100164354.5y
- Jun 3, 2031method-of-use (U-3422)US 104784394.5y
- Jun 3, 2031method-of-use (U-3845)US 104784394.5y
- Jun 3, 2031method-of-use (U-3422)US 104784394.5y
- Jun 3, 2031method-of-use (U-3422)US 104784394.5y
- Jun 3, 2031method-of-use (U-3422)US 104784394.5y
- Jun 3, 2031method-of-use (U-1684)US 104784394.5y
- Jun 3, 2031method-of-use (U-3422)US 104784394.5y
- Jun 3, 2031method-of-use (U-1456)US 106536964.5y
- Jun 3, 2031method-of-use (U-2943)US 107513424.5y
- Jun 3, 2031method-of-use (U-1491)US 107513424.5y
- Jun 3, 2031method-of-use (U-2943)US 107513424.5y
- Jun 3, 2031method-of-use (U-2943)US 107513424.5y
- Jun 3, 2031method-of-use (U-2943)US 107513424.5y
- Jun 3, 2031method-of-use (U-1491)US 107513424.5y
- Jun 3, 2031method-of-use (U-3842)US 107513424.5y
- Jun 3, 2031method-of-use (U-2242)US 116728034.5y
- Jun 3, 2031method-of-use (U-1946)US 116728034.5y
- Jun 3, 2031method-of-use (U-2242)US 116728034.5y
- Jun 3, 2031method-of-use (U-1684)US 116728034.5y
- Jun 3, 2031method-of-use (U-2242)US 116728034.5y
- Jun 3, 2031method-of-use (U-3843)US 116728034.5y
- Jun 3, 2031method-of-use (U-1456)US 87540904.5y
- Jun 3, 2031method-of-use (U-1491)US 89999994.5y
- Jun 3, 2031method-of-use (U-1946)US 89999994.5y
- Jun 3, 2031method-of-use (U-1946)US 89999994.5y
- Jun 3, 2031method-of-use (U-3844)US 89999994.5y
- Jun 3, 2031method-of-use (U-1946)US 89999994.5y
- Jun 3, 2031method-of-use (U-2242)US 89999994.5y
- Jun 3, 2031method-of-use (U-1683)US 89999994.5y
- Jun 3, 2031method-of-use (U-1650)US 91258894.5y
- Jun 3, 2031method-of-use (U-3845)US 91258894.5y
- Jun 3, 2031method-of-use (U-1745)US 91258894.5y
- Jun 3, 2031method-of-use (U-1650)US 91258894.5y
- Jun 3, 2031method-of-use (U-1650)US 91258894.5y
- Jun 3, 2031method-of-use (U-1650)US 91258894.5y
- Jun 3, 2031method-of-use (U-1650)US 91258894.5y
- Jun 3, 2031method-of-use (U-3847)US 98018814.5y
- Jun 3, 2031method-of-use (U-2242)US 98018814.5y
- Jun 3, 2031method-of-use (U-2242)US 98018814.5y
- Jun 3, 2031method-of-use (U-1491)US 98018814.5y
- Jun 3, 2031method-of-use (U-2242)US 98018814.5y
- Jun 3, 2031method-of-use (U-1491)US 98018814.5y
- Jun 3, 2031method-of-use (U-1491)US 98018814.5y
- Jun 3, 2031method-of-use (U-2243)US 98018834.5y
- Jun 3, 2031method-of-use (U-2159)US 98018834.5y
- Jun 3, 2031method-of-use (U-2159)US 98018834.5y
- Jun 3, 2031method-of-use (U-2159)US 98018834.5y
- Jun 3, 2031method-of-use (U-3844)US 98018834.5y
- Jun 3, 2031method-of-use (U-2243)US 98018834.5y
- Jun 3, 2031method-of-use (U-2159)US 98018834.5y
- Jun 3, 2031method-of-use (U-1947)US 98147214.5y
- May 13, 2028patentUS 8008309*PED1.5y
- May 13, 2028patentUS 8008309*PED1.5y
- May 13, 2028patentUS 8008309*PED1.5y
- May 13, 2028patentUS 8008309*PED1.5y
- May 13, 2028patentUS 8008309*PED1.5y
- May 13, 2028patentUS 8008309*PED1.5y
- May 13, 2028patentUS 8008309*PED1.5y
- Nov 13, 2027compositionUS 8008309356d
- Nov 13, 2027compositionUS 8008309356d
- Nov 13, 2027compositionUS 8008309356d
- Nov 13, 2027compositionUS 8008309356d
- Nov 13, 2027compositionUS 8008309356d
- Nov 13, 2027compositionUS 8008309356d
- Nov 13, 2027compositionUS 8008309356d
- Oct 26, 2027patentUS 8563563*PED338d
- Oct 26, 2027patentUS 8563563*PED338d
- Oct 26, 2027patentUS 8563563*PED338d
- Oct 26, 2027patentUS 8563563*PED338d
- Oct 26, 2027patentUS 8563563*PED338d
- Oct 26, 2027patentUS 8563563*PED338d
- Jun 28, 2027patentUS 7514444*PED218d
- Jun 28, 2027patentUS 7514444*PED218d
- Jun 28, 2027patentUS 7514444*PED218d
- Jun 28, 2027patentUS 7514444*PED218d
- Jun 28, 2027patentUS 7514444*PED218d
- Jun 28, 2027patentUS 7514444*PED218d
- Jun 28, 2027patentUS 7514444*PED218d
- Jun 28, 2027patentUS 8476284*PED218d
- Jun 28, 2027patentUS 8476284*PED218d
- Jun 28, 2027patentUS 8476284*PED218d
- Jun 28, 2027patentUS 8476284*PED218d
- Jun 28, 2027patentUS 8476284*PED218d
- Jun 28, 2027patentUS 8476284*PED218d
- Jun 28, 2027patentUS 8497277*PED218d
- Jun 28, 2027patentUS 8497277*PED218d
- Jun 28, 2027patentUS 8497277*PED218d
- Jun 28, 2027patentUS 8497277*PED218d
- Jun 28, 2027patentUS 8497277*PED218d
- Jun 28, 2027patentUS 8497277*PED218d
- Jun 28, 2027patentUS 8497277*PED218d
- Jun 28, 2027patentUS 8697711*PED218d
- Jun 28, 2027patentUS 8697711*PED218d
- Jun 28, 2027patentUS 8697711*PED218d
- Jun 28, 2027patentUS 8697711*PED218d
- Jun 28, 2027patentUS 8697711*PED218d
- Jun 28, 2027patentUS 8697711*PED218d
- Jun 28, 2027patentUS 8697711*PED218d
- Jun 28, 2027patentUS 8703780*PED218d
- Jun 28, 2027patentUS 8703780*PED218d
- Jun 28, 2027patentUS 8703780*PED218d
- Jun 28, 2027patentUS 8703780*PED218d
- Jun 28, 2027patentUS 8703780*PED218d
- Jun 28, 2027patentUS 8703780*PED218d
- Jun 28, 2027patentUS 8735403*PED218d
- Jun 28, 2027patentUS 8735403*PED218d
- Jun 28, 2027patentUS 8735403*PED218d
- Jun 28, 2027patentUS 8735403*PED218d
- Jun 28, 2027patentUS 8735403*PED218d
- Jun 28, 2027patentUS 8735403*PED218d
- Jun 28, 2027patentUS 8735403*PED218d
- Jun 28, 2027patentUS 8754091*PED218d
- Jun 28, 2027patentUS 8754091*PED218d
- Jun 28, 2027patentUS 8754091*PED218d
- Jun 28, 2027patentUS 8754091*PED218d
- Jun 28, 2027patentUS 8754091*PED218d
- Jun 28, 2027patentUS 8754091*PED218d
- Jun 28, 2027patentUS 8754091*PED218d
- Jun 28, 2027patentUS 8952015*PED218d
- Jun 28, 2027patentUS 8952015*PED218d
- Jun 28, 2027patentUS 8952015*PED218d
- Jun 28, 2027patentUS 8952015*PED218d
- Jun 28, 2027patentUS 8952015*PED218d
- Jun 28, 2027patentUS 8952015*PED218d
- Jun 28, 2027patentUS 8957079*PED218d
- Jun 28, 2027patentUS 8957079*PED218d
- Jun 28, 2027patentUS 8957079*PED218d
- Jun 28, 2027patentUS 8957079*PED218d
- Jun 28, 2027patentUS 8957079*PED218d
- Jun 28, 2027patentUS 8957079*PED218d
- Jun 28, 2027patentUS 8957079*PED218d
- Jun 28, 2027patentUS 9181257*PED218d
- Jun 28, 2027patentUS 9181257*PED218d
- Jun 28, 2027patentUS 9181257*PED218d
- Jun 28, 2027patentUS 9181257*PED218d
- Jun 28, 2027patentUS 9181257*PED218d
- Jun 28, 2027patentUS 9181257*PED218d
- Jun 28, 2027patentUS 9181257*PED218d
- Apr 26, 2027method-of-use (U-1491)US 8563563155d
- Apr 26, 2027method-of-use (U-1491)US 8563563155d
- Apr 26, 2027method-of-use (U-2241)US 8563563155d
- Apr 26, 2027method-of-use (U-3845)US 8563563155d
- Apr 26, 2027method-of-use (U-1491)US 8563563155d
- Apr 26, 2027method-of-use (U-2242)US 8563563155d
- Apr 26, 2027method-of-use (U-1491)US 8563563155d
- Dec 28, 2026compositionUS 751444436d
- Dec 28, 2026compositionUS 751444436d
- Dec 28, 2026compositionUS 751444436d
- Dec 28, 2026compositionUS 751444436d
- Dec 28, 2026compositionUS 751444436d
- Dec 28, 2026compositionUS 751444436d
- Dec 28, 2026compositionUS 751444436d
- Dec 28, 2026method-of-use (U-1650)US 847628436d
- Dec 28, 2026method-of-use (U-3845)US 847628436d
- Dec 28, 2026method-of-use (U-1946)US 847628436d
- Dec 28, 2026method-of-use (U-2241)US 847628436d
- Dec 28, 2026method-of-use (U-2241)US 847628436d
- Dec 28, 2026method-of-use (U-1946)US 847628436d
- Dec 28, 2026method-of-use (U-1650)US 847628436d
- Dec 28, 2026method-of-use (U-1650)US 849727736d
- Dec 28, 2026method-of-use (U-2242)US 849727736d
- Dec 28, 2026method-of-use (U-3422)US 849727736d
- Dec 28, 2026method-of-use (U-2970)US 849727736d
- Dec 28, 2026method-of-use (U-1491)US 849727736d
- Dec 28, 2026method-of-use (U-3422)US 849727736d
- Dec 28, 2026method-of-use (U-1456)US 849727736d
- Dec 28, 2026compositionUS 869771136d
- Dec 28, 2026compositionUS 869771136d
- Dec 28, 2026compositionUS 869771136d
- Dec 28, 2026compositionUS 869771136d
- Dec 28, 2026compositionUS 869771136d
- Dec 28, 2026compositionUS 869771136d
- Dec 28, 2026compositionUS 869771136d
- Dec 28, 2026method-of-use (U-3842)US 870378036d
- Dec 28, 2026method-of-use (U-2242)US 870378036d
- Dec 28, 2026method-of-use (U-2242)US 870378036d
- Dec 28, 2026method-of-use (U-1491)US 870378036d
- Dec 28, 2026method-of-use (U-1491)US 870378036d
- Dec 28, 2026method-of-use (U-2242)US 870378036d
- Dec 28, 2026method-of-use (U-1491)US 870378036d
- Dec 28, 2026compositionUS 873540336d
- Dec 28, 2026compositionUS 873540336d
- Dec 28, 2026compositionUS 873540336d
- Dec 28, 2026compositionUS 873540336d
- Dec 28, 2026compositionUS 873540336d
- Dec 28, 2026compositionUS 873540336d
- Dec 28, 2026compositionUS 873540336d
- Dec 28, 2026formulationUS 875409136d
- Dec 28, 2026formulationUS 875409136d
- Dec 28, 2026formulationUS 875409136d
- Dec 28, 2026formulationUS 875409136d
- Dec 28, 2026formulationUS 875409136d
- Dec 28, 2026formulationUS 875409136d
- Dec 28, 2026formulationUS 875409136d
- Dec 28, 2026method-of-use (U-1946)US 895201536d
- Dec 28, 2026method-of-use (U-2241)US 895201536d
- Dec 28, 2026method-of-use (U-1491)US 895201536d
- Dec 28, 2026method-of-use (U-1946)US 895201536d
- Dec 28, 2026method-of-use (U-1491)US 895201536d
- Dec 28, 2026method-of-use (U-3845)US 895201536d
- Dec 28, 2026method-of-use (U-1946)US 895201536d
- Dec 28, 2026compositionUS 895707936d
- Dec 28, 2026compositionUS 895707936d
- Dec 28, 2026compositionUS 895707936d
- Dec 28, 2026compositionUS 895707936d
- Dec 28, 2026compositionUS 895707936d
- Dec 28, 2026compositionUS 895707936d
- Dec 28, 2026compositionUS 895707936d
- Dec 28, 2026compositionUS 918125736d
- Dec 28, 2026compositionUS 918125736d
- Dec 28, 2026compositionUS 918125736d
- Dec 28, 2026compositionUS 918125736d
- Dec 28, 2026compositionUS 918125736d
- Dec 28, 2026compositionUS 918125736d
- Dec 28, 2026compositionUS 918125736d
FDA exclusivities (28)
- Feb 24, 2030PEDPediatric (6mo bonus)3.3y
- Feb 24, 2030PEDPediatric (6mo bonus)3.3y
- Feb 24, 2030PEDPediatric (6mo bonus)3.3y
- Feb 24, 2030PEDPediatric (6mo bonus)3.3y
- Feb 24, 2030PEDPediatric (6mo bonus)3.3y
- Feb 24, 2030PEDPediatric (6mo bonus)3.3y
- Feb 24, 2030PEDPediatric (6mo bonus)3.3y
- Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
- Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
- Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
- Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
- Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
- Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
- Aug 24, 2029ODE-405Orphan Drug (7y)2.8y
- Feb 24, 2026PEDPediatric (6mo bonus)
- Feb 24, 2026PEDPediatric (6mo bonus)
- Feb 24, 2026PEDPediatric (6mo bonus)
- Feb 24, 2026PEDPediatric (6mo bonus)
- Feb 24, 2026PEDPediatric (6mo bonus)
- Feb 24, 2026PEDPediatric (6mo bonus)
- Feb 24, 2026PEDPediatric (6mo bonus)
- Aug 24, 2025NPPNew Product (3y)
- Aug 24, 2025NPNP
- Aug 24, 2025NPPNew Product (3y)
- Aug 24, 2025NPPNew Product (3y)
- Aug 24, 2025NPPNew Product (3y)
- Aug 24, 2025NPPNew Product (3y)
- Aug 24, 2025NPPNew Product (3y)
News(6)
- 5 acquisitions that forced Big Pharmas to co-parentAcquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” acco…biospace · 4d ago
- Nurix drops one BTK degrader as momentum builds behind Roche-partnered optionNurix’s BTK degrader zelebrudomide may have survived a clinical hold in recent years, but that hasn’t stopped the California biotech from dropping the cancer drug.fiercebiotech · 1mo ago
- Pharma’s $500B patent problem will come in waves — not as a cliffMerck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.biopharma_dive · 1mo ago
- J&J dips despite upbeat outlook; AstraZeneca, Spero cut China dealsJ&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.biopharma_dive · 4mo ago
- Ibrutinib Monotherapy Yields Decade-Long Durable Efficacy in Across CLL SubtypesIbrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.onclive · 6mo ago
- Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCLRetrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.onclive · 6mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that